How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

457 results for

Pulmonary Hypertension in Sickle Cell Anemia

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

2. Pulmonary hypertension in Nigerian adults with sickle cell anemia (PubMed)

Pulmonary hypertension in Nigerian adults with sickle cell anemia Sickle cell anemia (SCA) is the commonest hemoglobinopathy and is associated with high morbidity and mortality. Pulmonary hypertension (PH) is reported to play a significant role in this regard. There is very limited literature on PH in SCA in Nigeria.The objectives of this study were to determine the prevalence of Doppler-derived PH in SCA, assess its influence on exercise capacity, and determine the correlates and predictors (...) of measures of estimated pulmonary pressure.A total of 92 SCA subjects had echocardiography and 6-minute self-paced walking exercise. PH was diagnosed by Doppler echocardiography on finding a tricuspid regurgitant velocity (TRV) of ≥2.5 m/s. The pulmonary flow profile was also assessed to estimate mean pulmonary arterial pressure (MPAP).Doppler-derived PH was detected in 23.9% of adults with SCA. The 6-minute walking distance (6MWD) was significantly lower in SCA adults with PH than in those without PH

Full Text available with Trip Pro

2017 Vascular health and risk management

3. Pulmonary Hypertension in Sickle Cell Anemia

Pulmonary Hypertension in Sickle Cell Anemia Pulmonary Hypertension in Sickle Cell Anemia Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer (...) Administration 4 Pulmonary Hypertension in Sickle Cell Anemia Pulmonary Hypertension in Sickle Cell Anemia Aka: Pulmonary Hypertension in Sickle Cell Anemia , Sickle Cell Anemia Related Pulmonary Hypertension From Related Chapters II. Epidemiology : Up to 30% of adults III. Symptoms IV. Signs Increased V. Imaging Right ventricular enlargement Tricuspid regiurgitation VI. Prognosis Increases mortality risk 10 fold VII. References Images: Related links to external sites (from Bing) These images are a random

2018 FP Notebook

4. Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease: An Official ATS Clinical Practice Guideline

Diagnosis, Risk Stratification, and Management of Pulmonary Hypertension of Sickle Cell Disease: An Official ATS Clinical Practice Guideline AMERICANTHORACICSOCIETY DOCUMENTS AnOf?cialAmericanThoracicSocietyClinicalPracticeGuideline: Diagnosis,RiskStrati?cation,andManagementofPulmonary HypertensionofSickleCellDisease Elizabeth S. Klings*, Roberto F. Machado*, Robyn J. Barst † , Claudia R. Morris, Kamal K. Mubarak, Victor R. Gordeuk, Gregory J. Kato, Kenneth I. Ataga, J. Simon Gibbs, Oswaldo (...) Castro, Erika B. Rosenzweig, Namita Sood, Lewis Hsu, KevinC.Wilson,MarilynJ.Telen,LauraM.DeCastro,LakshmananKrishnamurti,MartinH.Steinberg,DavidB.Badesch, and Mark T. Gladwin; on behalf of the ATS Ad Hoc Committee on Pulmonary Hypertension of Sickle Cell Disease THISOFFICIALCLINICALPRACTICEGUIDELINE OF THEAMERICANTHORACICSOCIETY WAS APPROVED BY THEATSBOARD OFDIRECTORS,NOVEMBER2013.THESE GUIDELINES WERE ALSO ENDORSED BY THE AMERICAN COLLEGE OF CHEST PHYSICIANS,OCTOBER 2013, AND BY THE PULMONARY

2014 American Thoracic Society

5. Thrombospondin-1 Gene Polymorphism is Associated with Estimated Pulmonary Artery Pressure in Patients with Sickle Cell Anemia (PubMed)

of Pittsburgh, Pittsburgh, Pennsylvania. eng K23 HL112848 HL NHLBI NIH HHS United States R01 HL121386 HL NHLBI NIH HHS United States R01 HL133864 HL NHLBI NIH HHS United States R01 MD009162 MD NIMHD NIH HHS United States Clinical Trial Letter Research Support, N.I.H., Extramural 2017 02 03 United States Am J Hematol 7610369 0361-8609 0 Thrombospondin 1 0 thrombospondin-1, human IM Anemia, Sickle Cell genetics physiopathology Blood Pressure Female Humans Hypertension, Pulmonary genetics physiopathology Male (...) Thrombospondin-1 Gene Polymorphism is Associated with Estimated Pulmonary Artery Pressure in Patients with Sickle Cell Anemia 28033687 2017 11 29 2019 01 09 1096-8652 92 3 2017 03 American journal of hematology Am. J. Hematol. Thrombospondin-1 gene polymorphism is associated with estimated pulmonary artery pressure in patients with sickle cell anemia. E31-E34 10.1002/ajh.24635 Jacob Seethal A SA 0000-0003-2906-6102 Division of Hematology/Oncology, Children's Hospital of Pittsburgh, Pittsburgh

Full Text available with Trip Pro

2017 American journal of hematology

6. Phosphodiesterase Type-5 Inhibitor Therapy in Sickle Cell People With Pulmonary Hypertension

Posted: January 23, 2019 Last Verified: January 15, 2019 Layout table for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) ): Outcomes Assessment Sickle Cell Disease Additional relevant MeSH terms: Layout table for MeSH terms Hypertension Hypertension, Pulmonary Anemia, Sickle Cell Vascular Diseases (...) Phosphodiesterase Type-5 Inhibitor Therapy in Sickle Cell People With Pulmonary Hypertension Phosphodiesterase Type-5 Inhibitor Therapy in Sickle Cell People With Pulmonary Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more

2018 Clinical Trials

7. Associations of α-thalassemia and BCL11A with stroke in Nigerian, United States, and United Kingdom sickle cell anemia cohorts (PubMed)

associations with clinical and laboratory variables than the individual genetic components in the University of Ibadan cohort (n=249). We then replicated our findings in SCA cohorts from the University of Illinois at Chicago (UIC)(n=260) and Walk-Treatment of Pulmonary Hypertension and Sickle cell disease with Sildenafil Therapy (Walk-PHaSST)(n=387). High-risk was associated with higher reticulocytes (15.0% vs. 7.8%, P=0.08) and stroke history (6% vs. 1%, P=0.02) than standard risk patients (...) Associations of α-thalassemia and BCL11A with stroke in Nigerian, United States, and United Kingdom sickle cell anemia cohorts Alpha-thalassemia and the BCL11A rs1427407 T allele are commonly observed in sickle cell anemia (SCA) patients and are associated with reduced hemolysis and higher hemoglobin F levels, respectively. We investigated whether a high-risk genetic profile, defined as SCA patients who did not inherit either α-thalassemia or the BCL11A rs1427407 T allele, had stronger

Full Text available with Trip Pro

2017 Blood advances

8. Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD)

to Share IPD: No Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Keywords provided by United Therapeutics: Oral treprostinil 6-Minute Walk Distance PH sickle cell Additional relevant MeSH terms: Layout table for MeSH terms Hypertension Hypertension, Pulmonary Anemia, Sickle Cell Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia (...) Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD) Study to Evaluate Efficacy and Safety of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Sickle Cell Disease (SCD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save

2017 Clinical Trials

9. Prostacyclin-analog therapy in sickle cell pulmonary hypertension. (PubMed)

Prostacyclin-analog therapy in sickle cell pulmonary hypertension. 28126964 2018 09 10 2018 11 13 1592-8721 102 5 2017 05 Haematologica Haematologica Prostacyclin-analog therapy in sickle cell pulmonary hypertension. e163-e165 10.3324/haematol.2015.131227 Weir Nargues A NA Cardiovascular and Pulmonary Branch, National Institutes of Health, Bethesda, MD. Saiyed Rehan R Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD. Alam Shoaib S (...) -Oncology, Department of Medicine, University of Pittsburgh School of Medicine, PA, USA katogj@upmc.edu. eng ZIA HL006014 HL NHLBI NIH HHS United States Letter Research Support, N.I.H., Intramural 2017 01 25 Italy Haematologica 0417435 0390-6078 0 Antihypertensive Agents DCR9Z582X0 Epoprostenol IM Adolescent Adult Anemia, Sickle Cell complications diagnosis Antihypertensive Agents therapeutic use Blood Pressure drug effects Echocardiography Epoprostenol analogs & derivatives therapeutic use Female

Full Text available with Trip Pro

2017 Haematologica

10. Pulmonary hypertension in chronic hemolytic anemias: Pathophysiology and treatment. (PubMed)

Pulmonary hypertension in chronic hemolytic anemias: Pathophysiology and treatment. Pulmonary hypertension has emerged as a major cause of morbidity and mortality in patients with hemoglobinopathies and chronic hemolytic anemias. These hematological diseases include - but are not limited to - sickle cell disease (SCD), thalassemia, paroxysmal nocturnal hematuria, and hereditary spherocytosis. Although most studies have been based on the use of echocardiography as a screening tool for pulmonary (...) hypertension as opposed to the gold standard of right heart catheterization for definitive diagnosis, the association between chronic hemolytic anemia and pulmonary hypertension is evident. Studies have shown that patients with SCD and a tricuspid regurgitant velocity (TRV) ≥ 2.5 m/sec are at increased risk of pulmonary hypertension and are at increased mortality risk. Additional markers of risk of pulmonary hypertension and increased mortality include a pro-BNP >160 pg/mL combined with a 6-min walk

2018 Respiratory medicine

11. Macitentan in Pulmonary Hypertension of Sickle Cell Disease

there is no plan to share IPD. Layout table for additional information Studies a U.S. FDA-regulated Drug Product: Yes Studies a U.S. FDA-regulated Device Product: No Keywords provided by Boston University: Pulmonary Hypertension Sickle Cell Disease Pulmonary Arterial Hypertension Macitentan Additional relevant MeSH terms: Layout table for MeSH terms Hypertension Hypertension, Pulmonary Anemia, Sickle Cell Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases Anemia, Hemolytic (...) Macitentan in Pulmonary Hypertension of Sickle Cell Disease Macitentan in Pulmonary Hypertension of Sickle Cell Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Macitentan in Pulmonary Hypertension

2016 Clinical Trials

12. MKSAP: 24-year-old woman with sickle cell anemia

MKSAP: 24-year-old woman with sickle cell anemia In sickle cell disease, transfusion is not indicated for uncomplicated pregnancy MKSAP: 24-year-old woman with sickle cell anemia | | January 21, 2017 2 Shares Test your medicine knowledge with the , in partnership with the . A 24-year-old woman undergoes routine evaluation. She is pregnant at 12 weeks’ gestation. Medical history is notable for homozygous sickle cell anemia (Hb SS). She has had multiple uncomplicated painful crises treated (...) of the following is the most appropriate management? A: Erythrocyte transfusion to maintain hemoglobin level at 10 g/dL (100 g/L) B: Erythropoiesis-stimulating agent C: Exchange transfusion D: No transfusion at this time MKSAP Answer and Critique The correct answer is D: No transfusion at this time. The patient should not receive an erythrocyte transfusion at this time. Erythrocyte transfusion in sickle cell disease (SCD) is appropriate only for specific indications, including stroke, symptomatic anemia, acute

2017 KevinMD blog

13. Kidney Function in Sickle Cell Anemia

characteristics for the worsening of kidney function and for a rapid decline in kidney function. "Funding Source - FDA OOPD" Condition or disease Sickle Cell Disease Kidney Failure, Chronic Detailed Description: Sickle cell disease is a severe monogenic disorder which affects approximately 80,000 patients in the US. It is characterized by a vasculopathy with involvement of multiple organs and resulting in complications such as ischemic stroke, pulmonary hypertension, autosplenectomy, priapism, as well (...) Kidney Function in Sickle Cell Anemia Kidney Function in Sickle Cell Anemia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Kidney Function in Sickle Cell Anemia The safety and scientific validity

2017 Clinical Trials

14. Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease

Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease - Qureshi - 2018 - British Journal of Haematology - Wiley Online Library By continuing to browse this site, you agree to its use of cookies as described in our . Search within Search term Search term The full text of this article hosted at iucr.org is unavailable due to technical difficulties. Guideline Free Access (...) Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease A British Society for Haematology Guideline Department of Paediatric Haematology and Oncology, Oxford Children's Hospital, Oxford University Hospital NHS Trust, Oxford, UK Department of Paediatric Haematology and Oncology, Royal London Hospitals, Barts Health NHS Trust, London, UK Department of Haematology, Sandwell and West Birmingham NHS Trust, West Bromwich, UK Department of Paediatric Haematology, Alderhey

Full Text available with Trip Pro

2018 British Committee for Standards in Haematology

15. Red cell transfusion in sickle cell disease Part II

) Sickle cell acute chest syndrome associated with parvovirus B19 infection: case series and review. Am J Hematol, 51, 207-213. Lusher, J.M., Haghighat, H. & Khalifa, A.S. (1976) A prophylactic transfusion program for children with sickle cell anemia complicated by CNS infarction. Am J Hematol, 1, 265-273. Machado, R.F. & Gladwin, M.T. (2005) Chronic sickle cell lung disease: new insights into the diagnosis, pathogenesis and treatment of pulmonary hypertension. Br J Haematol, 129, 449-464. Malinowski (...) . (2005) Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med, 353, 2769-2778. Adams, R.J., McKie, V.C., Hsu, L., Files, B., Vichinsky, E., Pegelow, C., Abboud, M., Gallagher, D., Kutlar, A., Nichols, F.T., Bonds, D.R. & Brambilla, D. (1998) Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. The New England Journal of Medicine, 339, 5-11. Anderson, M.J., Kidd, I.M

2016 British Committee for Standards in Haematology

16. Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology (PubMed)

Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology Cardiopulmonary complications are the leading cause of mortality in sickle cell anemia (SCA). Elevated tricuspid regurgitant jet velocity, pulmonary hypertension, diastolic, and autonomic dysfunction have all been described, but a unifying pathophysiology and mechanism explaining the poor prognosis and propensity to sudden death has been elusive. Herein, SCA mice underwent a longitudinal comprehensive cardiac (...) analysis, combining state-of-the-art cardiac imaging with electrocardiography, histopathology, and molecular analysis to determine the basis of cardiac dysfunction. We show that in SCA mice, anemia-induced hyperdynamic physiology was gradually superimposed with restrictive physiology, characterized by progressive left atrial enlargement and diastolic dysfunction with preserved systolic function. This phenomenon was absent in WT mice with experimentally induced chronic anemia of similar degree

Full Text available with Trip Pro

2016 Proceedings of the National Academy of Sciences of the United States of America

17. Biochemical surrogate markers of hemolysis do not correlate with directly measured erythrocyte survival in sickle cell anemia. (PubMed)

Biochemical surrogate markers of hemolysis do not correlate with directly measured erythrocyte survival in sickle cell anemia. Hemolysis is a key feature of sickle cell anemia (HbSS). Direct quantitation of hemolysis could be used as an objective outcome in clinical trials of new therapeutics for HbSS and would also enable better human studies of the pathogenesis of complications of HbSS that are ostensibly hemolysis-related, such as pulmonary hypertension. However, contemporary human studies

Full Text available with Trip Pro

2016 American journal of hematology

18. CRACKCAST E121 – Anemia, Polycythemia, and White Blood Cell Disorders

) Iron deficiency, Vitamin B12/folate deficiency, Aplastic anemia, Myeloid metaplasia with myelofibrosis, Hypoendocrine state, Renal disease [4] List 5 causes of MAHA (review question) DIC, TTP, HUS, Malignant hypertension, Preeclampsia [5] What organ damage is seen in sickle cell disease? Skin – stasis ulcer CNS – CVA Eye – retinal hemorrhage, retinopathy Cardiac – CHF Pulmonary – PE, infarct, infection Vascular – occlusive phenomenon ANYWHERE Liver – infarct, transfusion-related hepatitis, hepatic (...) ] List 4 intrinsic and 4 extrinsic causes of hemolytic anemia Refer to box 112.8 for intrinsic and extrinsic causes of hemolytic anemia Intrinsic Causes of Hemolytic Anemia Enzyme defect (pyruvate kinase deficiency, G6PD deficiency) Membrane defect (spherocytosis, elliptostomatocytosis, paroxysmal nocturnal hemoglobinuria) Hemoglobin defect (Thalassemias, hemoglobin M, unstable hemoglobin, sickle cell) Extrinsic Causes of Hemolytic Anemia Immunologic (allo or autoantibodies) Mechanical

2017 CandiEM

19. Pulmonary Endarterectomy as Treatment for Chronic Thromboembolic Pulmonary Hypertension in Sickle Cell Disease (PubMed)

Pulmonary Endarterectomy as Treatment for Chronic Thromboembolic Pulmonary Hypertension in Sickle Cell Disease 26370739 2016 06 02 2018 11 13 1096-8652 90 12 2015 Dec American journal of hematology Am. J. Hematol. Pulmonary endarterectomy as treatment for chronic thromboembolic pulmonary hypertension in sickle cell disease. E223-4 10.1002/ajh.24192 Freeman Ashley T AT Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Ataga Kenneth I KI (...) Division of Hematology/Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. eng R01 HL111659 HL NHLBI NIH HHS United States U01 HL117659 HL NHLBI NIH HHS United States R01HL111659 HL NHLBI NIH HHS United States U01HL117659 HL NHLBI NIH HHS United States Case Reports Letter Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't 2015 11 17 United States Am J Hematol 7610369 0361-8609 IM Adult Anemia, Sickle Cell complications surgery Endarterectomy methods

Full Text available with Trip Pro

2015 American journal of hematology

20. Chronic Pulmonary Complications of Sickle Cell Disease. (PubMed)

Chronic Pulmonary Complications of Sickle Cell Disease. Sickle cell disease (SCD), the most common genetic hemolytic anemia worldwide, affects 250,000 births annually. In the United States, SCD affects approximately 100,000 individuals, most of African descent. Hemoglobin S (HbS) results from a glutamate-to-valine mutation of the sixth codon of the β-hemoglobin allele; the homozygous genotype (HbSS) is associated with the most prevalent and severe form of the disease. Other SCD genotypes (...) of these conditions has improved much over the past 10 to 15 years, there remains no specific treatment for pulmonary complications of SCD. It is unclear whether conventional treatment regimens directed at non-SCD populations have equivalent efficacy in patients with SCD. This represents a critical research need. In this review, the authors review the state-of-the-art understanding of the following pulmonary complications of SCD: (1) pulmonary hypertension; (2) venous thromboembolic disease; (3) sleep-disordered

Full Text available with Trip Pro

2016 Chest

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>